Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Bortezomib Improves Survival of Newly Diagnosed Patients with Multiple Myeloma
(Posted: 09/11/2008, Updated: 05/04/2010) - The targeted drug bortezomib, when added to standard therapy (melphalan and prednisone), improves survival of patients with newly diagnosed multiple myeloma, according to the May 1, 2010, issue of the Journal of Clinical Oncology.
- Dutasteride Decreases Prostate Cancer Risk
(Posted: 04/12/2010) - Results from a large randomized clinical trial indicate that men at an increased risk for prostate cancer reduced their risk with regular use of the drug dutasteride (Avodart).
- Drug Slows Progression of Cutaneous T-Cell Lymphoma
(Posted: 03/31/2010) - Patients with cutaneous T-cell lymphoma who received the drug denileukin diftitox survived without disease progression for a median of more than 2 years, compared with just over 4 months for patients who received a placebo, according to a study published March 8, 2010, in the Journal of Clinical Oncology.
- Internal Radiation Effectively Reduces Local Recurrence of Some Endometrial Cancers
(Posted: 03/31/2010) - Vaginal brachytherapy was as effective as external-beam radiation therapy at reducing the rate of cancer recurrence in the vagina and had fewer side effects for women with high-intermediate risk endometrial cancer, according to a study published March 6, 2010, in the The Lancet.
- Higher Radiation Dose Reduces "Biochemical Recurrence" of Prostate Cancer
(Posted: 10/03/2005, Updated: 03/15/2010) - Men with early-stage prostate cancer who received higher doses of radiation were less likely than men who received the conventional dose to have rising levels of prostate-specific antigen (PSA), a phenomenon referred to as “biochemical recurrence,” according to the March 1, 2010, issue of Journal of Clinical Oncology.